Have a feature idea you'd love to see implemented?
Let us know!
ZYME Zymeworks Inc
Price (delayed)
$13.87
Market cap
$985.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.51
Enterprise value
$934.5M
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of
Highlights
The quick ratio has surged by 59% year-on-year
The company's debt fell by 26% YoY and by 20% QoQ
Zymeworks's net income has shrunk by 160% YoY but it has increased by 11% QoQ
ZYME's EPS has dropped by 152% year-on-year but it is up by 15% since the previous quarter
The company's equity fell by 10% YoY and by 7% QoQ
Key stats
What are the main financial stats of ZYME
Market
Valuations
Earnings
Shares outstanding
71.05M
Market cap
$985.43M
Enterprise value
$934.5M
Price to book (P/B)
2.41
Price to sales (P/S)
16.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.9
Revenue
$62.71M
EBIT
-$115.98M
EBITDA
-$101.25M
Free cash flow
-$93.44M
Per share
Balance sheet
Liquidity
EPS
-$1.51
Free cash flow per share
-$1.22
Book value per share
$5.74
Revenue per share
$0.82
TBVPS
$6.5
Total assets
$515.63M
Total liabilities
$109.47M
Debt
$20.03M
Equity
$406.16M
Working capital
$328.78M
Debt to equity
0.05
Current ratio
7.01
Quick ratio
6.62
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
-161.5%
Gross margin
100%
Net margin
-179.4%
Operating margin
-219%
Return on assets
-20.4%
Return on equity
-26%
Return on invested capital
-30%
Return on capital employed
-25.2%
Return on sales
-185%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZYME stock price
How has the Zymeworks stock price performed over time
Intraday
1.24%
1 week
5.8%
1 month
10.52%
1 year
98.43%
YTD
33.49%
QTD
10.52%
Financial performance
How have Zymeworks's revenue and profit performed over time
Revenue
$62.71M
Gross profit
$62.71M
Operating income
-$137.35M
Net income
-$112.51M
Gross margin
100%
Net margin
-179.4%
ZYME's operating income has dropped by 173% year-on-year but it is up by 8% since the previous quarter
Zymeworks's net income has shrunk by 160% YoY but it has increased by 11% QoQ
Zymeworks's revenue has plunged by 86% YoY but it has increased by 24% from the previous quarter
Zymeworks's gross profit has shrunk by 86% YoY but it has increased by 24% QoQ
Growth
What is Zymeworks's growth rate over time
Valuation
What is Zymeworks stock price valuation
P/E
N/A
P/B
2.41
P/S
16.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.9
ZYME's EPS has dropped by 152% year-on-year but it is up by 15% since the previous quarter
ZYME's P/B is 70% above its last 4 quarters average of 1.4 but 18% below its 5-year quarterly average of 2.9
The company's equity fell by 10% YoY and by 7% QoQ
Zymeworks's revenue has plunged by 86% YoY but it has increased by 24% from the previous quarter
The stock's price to sales (P/S) is 81% more than its last 4 quarters average of 9.2 but 52% less than its 5-year quarterly average of 34.6
Efficiency
How efficient is Zymeworks business performance
Zymeworks's ROA has plunged by 159% YoY but it has increased by 7% from the previous quarter
Zymeworks's return on equity has shrunk by 156% YoY but it has increased by 8% QoQ
ZYME's ROIC has dropped by 139% year-on-year but it is up by 10% since the previous quarter
ZYME's ROS is up by 27% since the previous quarter
Dividends
What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZYME.
Financial health
How did Zymeworks financials performed over time
The quick ratio has surged by 59% year-on-year
The company's current ratio has surged by 56% YoY
The company's debt is 95% lower than its equity
The company's debt fell by 26% YoY and by 20% QoQ
The debt to equity is down by 17% since the previous quarter and by 17% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.